Schwab Charles Investment Management Inc. raised its holdings in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 25.2% during the fourth quarter, Holdings Channel reports. The fund owned 138,448 shares of the biotechnology company’s stock after buying an additional 27,868 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Aimmune Therapeutics were worth $5,237,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Citadel Advisors LLC grew its holdings in shares of Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after purchasing an additional 542,111 shares during the last quarter. State Street Corp grew its holdings in shares of Aimmune Therapeutics by 26.6% in the second quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after purchasing an additional 228,429 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Aimmune Therapeutics by 10.2% in the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after purchasing an additional 101,855 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Aimmune Therapeutics by 156.6% in the third quarter. Russell Investments Group Ltd. now owns 66,454 shares of the biotechnology company’s stock worth $1,648,000 after purchasing an additional 40,557 shares during the last quarter. Finally, Schroder Investment Management Group bought a new position in shares of Aimmune Therapeutics in the third quarter worth approximately $961,000. Institutional investors and hedge funds own 62.04% of the company’s stock.
Shares of Aimmune Therapeutics Inc (AIMT) opened at $33.28 on Thursday. Aimmune Therapeutics Inc has a 52 week low of $15.97 and a 52 week high of $42.00. The company has a market capitalization of $1,867.50, a price-to-earnings ratio of -12.75 and a beta of -0.49.
AIMT has been the topic of several recent analyst reports. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They issued a “buy” rating and a $60.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $70.00 target price on shares of Aimmune Therapeutics in a report on Friday, December 1st. ValuEngine cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Piper Jaffray Companies raised their price target on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 5th. Finally, Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $57.22.
In other Aimmune Therapeutics news, insider Daniel C. Md Adelman sold 3,283 shares of the firm’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $40.00, for a total transaction of $131,320.00. Following the completion of the transaction, the insider now owns 3,283 shares of the company’s stock, valued at $131,320. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bakker Juliet Tammenoms acquired 9,375 shares of the stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $32.00 per share, with a total value of $300,000.00. Following the transaction, the insider now directly owns 16,651 shares of the company’s stock, valued at approximately $532,832. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 58,093 shares of company stock valued at $1,858,976 and sold 133,968 shares valued at $5,073,180. Company insiders own 24.56% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.